• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Amgen

Amgen

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine

    Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine

  2. Amgen , Other Drug Company Shares Jump on Cholesterol Drug Findings

    Amgen , Other Drug Company Shares Jump on Cholesterol Drug Findings

  3. Amgen , other drug company shares jump on cholesterol drug findings

    Amgen , other drug company shares jump on cholesterol drug findings

  4. UPDATE: Amgen , other drug company shares jump on cholesterol drug findings

    UPDATE: Amgen , other drug company shares jump on cholesterol drug findings

  5. DJ Amgen , Other Drug Company Shares Jump on Cholesterol Drug Findings

    DJ Amgen , Other Drug Company Shares Jump on Cholesterol Drug Findings

  6. New Detailed Data From Phase 3 Study Show Amgen's Repatha™ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular ...

    New Detailed Data From Phase 3 Study Show Amgen's Repatha™ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol

  7. Research and Markets: Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015

    Research and Markets: Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2015

  8. Research and Markets: Bone Metastasis Global Clinical Trials Review, H1, 2015

    Research and Markets: Bone Metastasis Global Clinical Trials Review, H1, 2015

  9. Technavio Publishes Global Melanoma Therapeutics Market Analysis and Forecast 2015-2019

    Technavio Publishes Global Melanoma Therapeutics Market Analysis and Forecast 2015-2019

  10. Judge Denies Amgen's Request to Block Novartis's Biosimilar of Neupogen

    Judge Denies Amgen's Request to Block Novartis's Biosimilar of Neupogen

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.